Adial Pharmaceuticals, Inc.
ADIL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001513525
In the last 90 days, Adial Pharmaceuticals, Inc. insiders filed 3 open-market purchases and 0 sales; 17 institutions reported holding it in 13F filings for Q2 2026, worth $334.6K in total; no superinvestor holds it.
13F holders, Q2 2021
Institutional positions in Adial Pharmaceuticals, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- −1 vs. Q1 2021
- Shares held
- 1.23M
- +427.6K (+53.0%) vs. Q1 2021
- Total value
- $3.15M
- +$1.19M (+61.2%) vs. Q1 2021
- New holders
- 4
- 6 more added
- Sold out
- 5
- 4 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ADIL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 17 | $334.6K |
| Q1 2026 | 15 | $63.8K |
| Q4 2025 | 24 | $778.4K |
| Q3 2025 | 17 | $214.8K |
| Q2 2025 | 17 | $70.8K |
| Q1 2025 | 14 | $152.7K |
| Q4 2024 | 15 | $298.1K |
| Q3 2024 | 12 | $195.9K |
| Q2 2024 | 16 | $328.0K |
| Q1 2024 | 16 | $236.2K |
| Q4 2023 | 17 | $495.3K |
| Q3 2023 | 11 | $164.2K |
| Q2 2023 | 21 | $488.2K |
| Q1 2023 | 23 | $876.9K |
| Q4 2022 | 23 | $359.2K |
| Q3 2022 | 28 | $692.1K |
| Q2 2022 | 26 | $2.27M |
| Q1 2022 | 23 | $6.38M |
| Q4 2021 | 24 | $3.61M |
| Q3 2021 | 21 | $5.50M |
| Q2 2021 | 19 | $3.15M |
| Q1 2021 | 20 | $1.95M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Adial Pharmaceuticals, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 585,035 | $1.49M | 0.00% | +370,238+172.4% | Added |
| BlackRock Inc. | 195,911 | $499.0K | 0.00% | −9,773−4.8% | Reduced |
| Geode Capital Management, LLC | 88,246 | $225.0K | 0.00% | +10,261+13.2% | Added |
| State Street Corp | 48,954 | $125.0K | 0.00% | +48,954 | New |
| Raffa Wealth Management, LLC | 41,845 | $106.7K | 0.04% | 00.0% | Unchanged |
| Private Advisor Group, LLC | 36,650 | $93.0K | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 31,410 | $80.0K | 0.00% | 00.0% | Unchanged |
| Virtu Financial LLC | 31,038 | $79.0K | 0.01% | +31,038 | New |
| Commonwealth Equity Services, LLC | 29,050 | $74.0K | 0.00% | +7,000+31.7% | Added |
| Oppenheimer & Co Inc | 28,000 | $71.0K | 0.00% | +13,500+93.1% | Added |
| Brown Advisory Inc | 26,040 | $66.0K | 0.00% | 00.0% | Unchanged |
| Golden Green, Inc. | 24,700 | $63.0K | 0.05% | +24,700 | New |
| Northern Trust Corp | 21,873 | $56.0K | 0.00% | +21,873 | New |
| Citadel Advisors LLC | 20,198 | $52.0K | 0.00% | −54,093−72.8% | Reduced |
| Rede Wealth, LLC | 15,200 | $39.0K | 0.02% | +200+1.3% | Added |
| Advisor Group Holdings, Inc. | 8,321 | $21.0K | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 823 | $2.00K | 0.00% | +15+1.9% | Added |
| Morgan Stanley | 535 | $1.00K | 0.00% | −4,665−89.7% | Reduced |
| Tower Research Capital LLC (TRC) | 464 | $1.00K | 0.00% | −901−66.0% | Reduced |
| Barclays PLC | 0 | $0 | 0.00% | −15,850−100.0% | Sold out |
| Creative Planning | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −4,447−100.0% | Sold out |
| Wealthcare Capital Management LLC | 0 | $0 | 0.00% | −375−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −125−100.0% | Sold out |